What happens during a M&A regulatory inspection in China?

Over 95% of cross-border merger filings submitted to China’s State Administration for Market Regulation (SAMR) clear Phase 1 review without conditions, yet the remaining minority can face delays exceeding six months — and failure to file at all can result in fines of up to RMB 500,000 alongside forced unwinding of the completed transaction. For any foreign business pursuing a merger or acquisition involving a Chinese counterpart, understanding what happens during a regulatory inspection is not optional; it is a legal necessity. China’s merger control regime, formally known as the concentration of undertakings review (经营者集中审查, jīngyíngzhě jízhōng shěnchá), has matured rapidly since the 2008 entry into force of the PRC Anti-Monopoly Law (AML). Today, SAMR’s Anti-Monopoly Bureau sits at the center of a review process that can determine whether a deal closes on schedule, closes with conditions, or does not close at all.

Overview of M&A Regulatory Inspections in China

A regulatory inspection in the context of Chinese M&A refers primarily to the merger control review conducted by SAMR under the AML. However, the term can also encompass sector-specific vetting by industry regulators such as the China Securities Regulatory Commission (CSRC), the National Development and Reform Commission (NDRC), the Ministry of Industry and Information Technology (MIIT), or the Cyberspace Administration of China (CAC). For the purposes of this FAQ, the focus is on the SAMR merger review process — the gate that most cross-border transactions must pass through — while also flagging key industry-specific overlays.

The inspection process is designed to assess whether a proposed concentration would eliminate or restrict competition in the Chinese market. The ultimate decision is grounded in economic analysis of market shares, market concentration indices (such as the Herfindahl-Hirschman Index), barriers to entry, the countervailing power of buyers, and the likely effects on technological development and consumer welfare. It is important to note that the review is forward-looking: SAMR evaluates the competitive effects of the transaction as proposed, not the historical conduct of the parties.

China’s merger review regime applies to concentrations of undertakings — a term that covers mergers, acquisitions of control, and joint ventures that are established on a full-function basis. A concentration is deemed to occur when (a) two or more previously independent undertakings merge, (b) one undertaking acquires control over another by purchasing assets, shares, or through contractual arrangements, or (c) two or more undertakings establish a joint venture that performs all functions of an autonomous economic entity on a lasting basis. The review is mandatory and suspensory: parties must not close the transaction before receiving clearance, a principle known as the standstill obligation (停顿义务, tíngdùn yìwù).

Regulatory Basis: Key Laws and Authorities

The legal foundation for M&A regulatory inspections in China rests on several interconnected statutes and regulations. Foreign businesses should be familiar with at least the following:

The Anti-Monopoly Bureau (反垄断局, fǎn lǒngduàn jú) within SAMR is the primary enforcement authority for merger control. Its decisions are informed by economic analysis conducted in-house and through consultations with industry associations, competitors, and customers. Since the 2022 revision of the AML, penalties for gun-jumping — closing a notifiable transaction before clearance — have increased substantially, and the amended law now explicitly empowers SAMR to impose restorative measures, including unwinding the transaction.

Industry-specific oversight adds another layer. A foreign acquirer in the financial sector must obtain approval from the CSRC or the National Financial Regulatory Administration (NFRA, formerly CBIRC). Transactions in telecommunications and media require MIIT clearance. If the target operates in defense, dual-use technology, energy, or critical infrastructure, a separate national security review (国家安全审查, guójiā ānquán shěnchá) under the 2021 Measures for the Security Review of Foreign Investments may apply. Since 2023, SAMR and the CAC have also increased coordination on data security reviews for platform economy and data-rich targets.

The Merger Review Process: Step by Step

The merger review process in China follows a structured, two-phase framework with a preliminary consultation stage that is increasingly common in practice. Here is how it unfolds from the perspective of a foreign filer:

1. Pre-filing consultation (预咨询, yù zīxún). Although not mandatory, SAMR strongly encourages parties to engage in informal pre-filing discussions. During this stage, the parties present the transaction structure, identify relevant markets, and seek SAMR’s preliminary views on whether a formal filing is required and which review track — simplified or standard — is likely to apply. Pre-filing consultations can take 2 to 8 weeks and are conducted on a no-names basis if confidentiality is a concern.
2. Formal filing (申报, shēnbào). Once the parties are ready, they submit a complete notification package to SAMR. The package must include the notification form, copies of the concentration agreement, business reports of the parties, market definition and share data, and an analysis of the competitive effects. SAMR acknowledges receipt and checks for completeness. If the materials are incomplete, the clock does not start. This “stop-the-clock” mechanism is a critical detail: SAMR can issue supplementary notice requests, and the review period does not run while the parties prepare additional information.
3. Phase 1 review (初步审查, chūbù shěnchá). SAMR has 30 calendar days from formal acceptance to complete the initial review. In practice, the average Phase 1 duration is approximately 24 days, according to SAMR’s own statistics published in its annual enforcement reports. During Phase 1, SAMR determines whether the concentration raises prima facie competition concerns. If no concerns are identified, SAMR issues a clearance decision (无条件批准, wú tiáojiàn pīzhǔn) — unconditional approval. Approximately 95–97% of filings are resolved at this stage. If concerns are identified, the case proceeds to Phase 2.
4. Phase 2 review (进一步审查, jìnyībù shěnchá). The in-depth investigation phase lasts 90 calendar days from the date the Phase 2 decision is communicated to the parties. SAMR may extend this period by an additional 60 calendar days with the consent of the parties or where the complexity of the case warrants it. During Phase 2, SAMR may conduct on-site inspections, request data from third parties (competitors, upstream suppliers, downstream distributors), hold hearings, and commission economic analyses. The parties may submit proposed remedies at any point during this phase. In practice, Phase 2 cases take between 60 and 150 days of active review time, not counting any period during which the clock is stopped pending the submission of additional data.
5. Decision. At the conclusion of the review, SAMR issues one of three outcomes: unconditional clearance, conditional clearance with remedies, or prohibition of the concentration. Prohibitions are rare — fewer than 2% of Phase 2 cases since 2008 have resulted in outright prohibition — but the threat of prohibition often drives parties to negotiate remedies early.

The entire process, from the start of pre-filing consultation to final decision, typically spans 3 to 9 months for a standard-track filing. Simplified procedure cases, discussed below, can close in 30 to 45 days.

Key Documents and Filing Requirements

The quality of the filing submission is the single most important factor in determining how smoothly a review proceeds. SAMR’s Interim Provisions on the Review of Concentrations of Undertakings specify the required documentation. The core submission package includes:

• Notification form (申报书, shēnbàoshū). A standardized form available from SAMR’s online platform, requiring detailed information on the parties, the transaction structure, the relevant product and geographic markets, market shares, and a description of the competitive effects.
• Copies of the concentration agreement. This includes the share purchase agreement (SPA), asset purchase agreement, or joint venture contract, as applicable. If executed versions are not yet available, draft versions may be accepted, but SAMR will typically require final execution before issuing clearance.
• Business reports (财务及业务报告, cáiwù jí yèwù bàogào). Audited financial statements for the most recent fiscal year, together with internal business reports describing the parties’ operations in China, including production capacity, sales volume, pricing strategies, and distribution channels.
• Market analysis report. A detailed competitive assessment that defines the relevant market, calculates market shares (in value and volume), identifies the top competitors, and analyzes barriers to entry, switching costs, and potential pro-competitive efficiencies that the concentration will generate. Foreign filers are strongly advised to engage a Chinese economic consultancy with experience in SAMR submissions for this component.
• Internal decision documents. Board resolutions, minutes of shareholders’ meetings, or other authorizing documents that demonstrate corporate approval of the transaction.
• Power of attorney. A formal authorization letter (授权委托书, shòuquán wěituōshū) if a law firm or third-party consultant is handling the filing on behalf of the parties.
• Industry-specific licenses. If the target operates in a regulated sector, copies of relevant licenses, permits, or approvals from sector regulators (CSRC, MIIT, NFRA, etc.).

All documents must be submitted in Chinese or accompanied by a certified Chinese translation. SAMR does not accept English-language submissions as complete. The online filing portal, accessible via the SAMR website, has become the primary filing channel since 2020, though physical submissions are still accepted in practice. Parties should budget for translation, notarization, and potential apostille costs, which can range from RMB 50,000 to RMB 200,000 depending on the complexity and volume of documents.

Timeline and Review Phases

Understanding the timeline expectations is critical for deal planning. Below is a summary of the statutory and average timelines at each stage:

The simplified procedure, significantly expanded in February 2024 under SAMR’s revised guidelines, is available for transactions where: (a) the parties have no horizontal overlap and no vertical or conglomerate relationships, or (b) the combined market share in any relevant market is below 15% for horizontal overlaps or below 25% for vertical relationships, or (c) a joint venture is established outside China and does not produce goods or provide services inside China. The simplified procedure shortens the public comment period and reduces documentation requirements, making it a popular option for foreign-to-foreign transactions with limited China nexus. In the first half of 2024, over 60% of all SAMR filings qualified for simplified treatment.

Digital economy and platform economy transactions face increased scrutiny under guidelines issued by SAMR in 2023 and 2024. The guidelines emphasize that factors such as network effects, data accumulation, the ability to leverage data across markets, and the potential for algorithmic coordination will be considered when assessing the competitive effects of digital market concentrations. Foreign acquirers of Chinese tech platforms should budget for Phase 2 review even when market shares appear modest, because SAMR’s analysis in digital markets extends beyond traditional market share thresholds to encompass data access and innovation effects.

Potential Outcomes and Remedies

When SAMR identifies competition concerns during the review, it does not reflexively prohibit the transaction. Instead, it engages with the parties to negotiate remedies that address the identified concerns while allowing the deal to proceed. Remedies fall into two broad categories:

• Behavioral remedies (行为性救济, xíngwéixìng jiùjì). These are ongoing commitments by the parties to conduct their business in a specified manner. Common examples include: commitments to supply competitors on fair, reasonable, and non-discriminatory (FRAND) terms; firewall arrangements to prevent the flow of competitively sensitive information between the merged entity and its affiliates; non-exclusivity commitments in distribution agreements; and commitments to continue investing in product development or infrastructure. Behavioral remedies are typically time-limited (3 to 5 years) and subject to monitoring by a SAMR-appointed supervisor or an independent trustee.
• Structural remedies (结构性救济, jiégòuxìng jiùjì). These involve the divestiture of assets, business units, or equity interests to restore competition. The classic structural remedy in Chinese merger control is the divestiture of an overlapping product line or a manufacturing facility to a SAMR-approved buyer. Structural remedies are permanent and are favored by SAMR when behavioral remedies are unlikely to be effective — for example, in markets with high barriers to entry or where the merged entity would have the ability and incentive to foreclose rivals. The divestiture must be completed within a specified time frame (typically 6 to 12 months), and the buyer must be pre-approved by SAMR under a “fix-it-first” or “upfront buyer” arrangement.

Conditional approvals account for roughly 2–3% of all filings. Notable recent examples include: the 2023 conditional approval of a foreign semiconductor equipment merger conditioned on FRAND licensing commitments and supply continuity guarantees; and the 2024 conditional clearance of a platform economy acquisition requiring data separation and algorithmic non-discrimination commitments. Prohibition decisions remain exceptionally rare — the most cited example remains the 2009 prohibition of the Coca-Cola/Huiyuan transaction — but the 2022 AML revision has given SAMR stronger tools, and enforcement against gun-jumping has risen sharply since 2023.

Penalties for Non-Compliance

China’s merger control regime operates on a mandatory-and-suspensory basis. Failure to comply — whether by closing before clearance (gun-jumping), providing false or misleading information, or violating the terms of a conditional approval — carries significant consequences. The 2022 revision of the AML introduced substantially increased penalty ceilings:

• Gun-jumping — closing without clearance. SAMR may impose a fine of up to 10% of the undertaking’s total turnover in the preceding fiscal year. For a large multinational, this can amount to billions of RMB. In addition, SAMR may order restorative measures, including the unwinding of the transaction (恢复原状, huīfù yuánzhuàng) — effectively forcing the parties to divest the acquired assets or shares. Since 2023, SAMR has issued gun-jumping penalties in several high-profile cases involving both domestic and foreign companies, including fines of RMB 300,000 to RMB 5,000,000 combined with orders to restore the pre-transaction competitive structure.
• Failure to notify despite meeting thresholds. Even if the transaction has not yet closed, failing to submit a mandatory filing can result in fines of up to RMB 500,000 under the pre-2022 regime, and significantly higher penalties under the revised AML if the failure is deemed willful or if it has caused competitive harm.
• Providing false or misleading information. SAMR may impose a fine of up to RMB 1,000,000 and, in serious cases, open a formal investigation for obstruction of the review process. The 2024 SAMR enforcement guidelines emphasize that deliberate omissions or misrepresentations in the notification form will be treated as aggravating factors.
• Violation of conditional approval terms. If the parties fail to comply with the behavioral or structural remedies imposed by SAMR, the authority may revoke the clearance decision, impose fines, and order the transaction to be unwound. SAMR may also appoint a compliance monitor at the parties’ expense.
• Reputational damage. Beyond the legal penalties, a gun-jumping finding is published on SAMR’s website and widely circulated in the business press. Foreign companies found to have violated China’s merger control rules may face increased scrutiny on future filings, longer review timelines, and damaged relationships with Chinese business partners and regulators.

The message for foreign businesses is clear: when in doubt, file. The cost and delay of submitting a filing (even where the outcome is a near-certain unconditional clearance) are minor compared to the legal, financial, and reputational consequences of failing to do so. Many multinationals maintain internal pre-clearance checklists that flag any transaction with a Chinese nexus for mandatory merger control assessment before the signing date.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: SLUG-TO-BE-FILLED]
• Still comparing? See [comparison: SLUG-TO-BE-FILLED]
• Need numbers? Try [tool: SLUG-TO-BE-FILLED]

— China Gateway 360 —
Remote China market entry support, built around execution.